At the Pujiang Prostate Cancer Academic Conference, Dr. Kan Gong (Peking University First Hospital) introduced an AI-driven diagnostic workflow that enhances prostate cancer precision care—from refined PSAD calculation to advanced patient risk stratification. Backed by award-winning data from EAU 2024, his team demonstrated that AI-guided targeted plus peri-lesional biopsy can match standard biopsy accuracy while using fewer cores, reducing complications, and streamlining diagnosis.
